These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16770092)

  • 1. [Molecular-targeted agents in breast cancer].
    Tokuda Y; Saito Y; Suzuki Y
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):747-53. PubMed ID: 16770092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of Herceptin in primary breast cancer: views from North America and Europe.
    Leyland-Jones B; Smith I
    Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel combined with targeted therapies in metastatic breast cancer.
    Cortes J; Roché H
    Cancer Treat Rev; 2012 Aug; 38(5):387-96. PubMed ID: 21872996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
    Eniu A
    J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combined chemotherapy with molecular-targeted agent for breast cancer].
    Ito Y; Miura H
    Gan To Kagaku Ryoho; 2008 May; 35(5):731-6. PubMed ID: 18487908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
    Khasraw M; Bell R
    Expert Rev Anticancer Ther; 2012 Aug; 12(8):1005-13. PubMed ID: 23030220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
    Fornier M; Esteva FJ; Seidman AD
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):38-45; discussion 92-100. PubMed ID: 11236027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
    Abair T; O'Shaughnessy J
    Clin Breast Cancer; 2011 Feb; 11(1):15-9. PubMed ID: 21989832
    [No Abstract]   [Full Text] [Related]  

  • 11. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
    Bullock K; Blackwell K
    Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
    Ross JS; Slodkowska EA; Symmans WF; Pusztai L; Ravdin PM; Hortobagyi GN
    Oncologist; 2009 Apr; 14(4):320-68. PubMed ID: 19346299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
    Altundag K; Baptista MZ
    Breast J; 2006; 12(5):497-8. PubMed ID: 16958977
    [No Abstract]   [Full Text] [Related]  

  • 17. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
    Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Possibilities and results with Herceptin-Taxol combination in the treatment of breast cancer].
    Láng I
    Magy Onkol; 2002; 46(2):195-6. PubMed ID: 12202900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ongoing and planned adjuvant trials with trastuzumab.
    Perez EA; Hortobagyi GN
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):26-32; discussion 92-100. PubMed ID: 11236024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.